Zentalis Pharmaceuticals Inc expected to post a loss of 71 cents a share - Earnings Preview

Zentalis Pharmaceuticals

05/03/2025 11:02

Zentalis Pharmaceuticals Inc ZNTL.OQ ZNTL.O is expected to show no change in quarterly revenue when it reports  results on March 7 (estimated) for the period ending December 31 2024

​LSEG's mean analyst estimate for Zentalis Pharmaceuticals Inc is for a loss of 71 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 6 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Zentalis Pharmaceuticals Inc is $6.00​, above​ its last closing price of $1.87. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATEÂŪ
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Sep. 30 2024
-0.88
-0.91
-0.56
Beat
38.5
Jun. 30 2024
-0.87
-0.84
-1.24
Missed
-47.5
Mar. 31 2024
-0.76
-0.77
0.14
Beat
118.3​
Dec. 31 2023
-0.94
-0.92
-0.93
Missed
-1.5
​​Sep. 30 2023
-0.91
-0.91
-0.79
Beat
13.3
Jun. 30 2023
-1.02
-1.04
-1.85
Missed
-78.3​
Mar. 31 2023
-0.98
-1.02
-1.07
Missed
-5
Dec. 31 2022
-1.01
-1.06
-0.92
Beat
13.2

This summary was machine generated March 5 at 11:01 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)